CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.

@article{Bettayeb2010CDKIR,
  title={CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.},
  author={Karima Bettayeb and Dianne Baunb{\ae}k and Claire Delehouze and Nad{\`e}ge Lo{\"a}ec and Alison J. Hole and Sonja Baumli and Jane A Endicott and S{\'e}tha Douc-Rasy and Jean B{\'e}nard and Nassima Oumata and Herv{\'e} Galons and Laurent Meijer},
  journal={Genes & cancer},
  year={2010},
  volume={1 4},
  pages={369-80}
}
Neuroblastoma (NB), the most frequent extracranial solid tumor of children accounting for nearly 15% of all childhood cancer mortality, displays overexpression of antiapoptotic Bcl-2 and Mcl-1 in aggressive forms of the disease. The clinical phase 2 drug roscovitine (CYC202, seliciclib), a relatively selective inhibitor of cyclin-dependent kinases (CDKs), and CR8, a recently developed and more potent analog, induce concentration-dependent apoptotic cell death of NB cells (average IC(50) values… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Design of Tat-Activated Cdk9 Inhibitor

International Journal of Peptide Research and Therapeutics • 2018
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 82 references

Similar Papers

Loading similar papers…